MoonLake Immunotherapeutics
MLTX
MLTX
131 hedge funds and large institutions have $270M invested in MoonLake Immunotherapeutics in 2025 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 32 increasing their positions, 40 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
33.33% less ownership
Funds ownership: 92.59% → 59.26% (-33%)
83% less funds holding in top 10
Funds holding in top 10: 6 → 1 (-5)
90% less capital invested
Capital invested by funds: $2.77B → $270M (-$2.5B)
Holders
131
Holding in Top 10
1
Calls
$33.1M
Puts
$14.4M
Top Buyers
| 1 | +$10.8M | |
| 2 | +$9.15M | |
| 3 | +$6.92M | |
| 4 |
Two Sigma Investments
New York
|
+$3.26M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.12M |
Top Sellers
| 1 | -$59.4M | |
| 2 | -$58.9M | |
| 3 | -$53.7M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$46.6M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$41.5M |
